SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of MacroGenics, Inc. (NASDAQ: MGNX) stock or sellers of MacroGenics puts between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), have until September 24, 2024 to seek appointment as lead plaintiff of the MacroGenics class action lawsuit. Captioned Crain v. MacroGenics, Inc., No. 24-cv-02184 (D. Md.), the MacroGenics class action lawsuit charges MacroGenics and MacroGenics' Chief Executive O ...

NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased the stock or sold puts of MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"). For more information, submit a form at MacroGenics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us ...

If you bought shares of MGNX between March 7, 2024 and May 9, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm's website at www.holzerlaw.com/case/macrogenics/ to learn more. CONTACT: Corey Holzer, Esq. (888) 508-6832 (toll-free) cholzer@holzerlaw.com ATLANTA, July 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action ...

The lawsuit alleges that MacroGenics and its executives made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, MacroGenics revealed that the drug was significantly more dangerous than previously represented, leading to a 77% decline in MacroGenics' stock price. What should you do next? If you have non-public information about MacroGenics, you should consider assisting in our investigation or working with our attorneys to file a re ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX's stock declined 77.4% ...

"We're investigating whether MacroGenics may have misled investors about its Phase 2 TAMARACK interim safety data," said Reed Kathrein, the Hagens Berman partner leading the investigation. Contact: Reed Kathrein, 844-916-0895 SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Investigation into MacroGenics, Inc. (MGNX): On Apr. 3, 2024, MacroGenics released interim safety data from the TAM ...

SAN FRANCISCO, July 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Contact the Firm Now: MGNX@hbsslaw.com 844-916-0895 The current investigation scrutinizes the accuracy of MacroGenics' statements regarding data from its Phase 2 TAMARACK study of the antibody-drug conjugate MGC018, known as "vobra duo," in patients with metastatic castration-resistant prostate cancer (mCRPC). However, the positive sentime ...

[Click here for information about joining the class action] NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether MacroGenics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On April ...

The investigation concerns whether MacroGenics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On April 3, 2024, MacroGenics announced Phase 2 TAMARACK interim safety data as contained in its abstract submitted to the American Society of Clinical Oncology on February 6, 2024. The Company reported that "[p]reliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in me ...

LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On this news, MacroGenics' st ...